Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.70 |
| ▸ | PPARG | P37231 | 9/20 | 0.70 |
| ▸ | PPARA | Q07869 | 9/20 | 0.70 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.56 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8439533 | 0.96 | PPARD (0.69) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL8443731 | 0.93 | PPARG (0.60) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL8442424 | 0.92 | PPARG (0.59) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL8443096 | 0.91 | PPARD (0.61) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL8439174 | 0.90 | PPARD (0.56) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL8442484 | 0.89 | PPARD (0.53) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL8443384 | 0.89 | PPARD (0.55) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL8443337 | 0.89 | PPARD (0.72) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL8442985 | 0.88 | PPARG (0.58) | PPARDPPARGPPARANR1H2NR1H3 | |
| SCHEMBL8443074 | 0.88 | PPARG (0.57) | PPARDPPARGPPARANR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888278-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 1999-06-30 | — | — | EP | claimed |
| EP-0888278-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997028115-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | claimed |
| EP-1259233-A1 | MODULATION OF BONE FORMATION | THE UNIVERSITY OF SHEFFIELD (GB) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060355-A1 | MODULATION OF BONE FORMATION | UNIVERSITY OF SHEFFIELD (GB) | 2001-08-23 | — | — | WO | disclosed |
| EP-0888278-A4 | ANTIDIABETIC AGENTS | MERCK & CO INC (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0888278-A1 | ANTIDIABETIC AGENTS | Merck & Co., Inc. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997028115-A1 | ANTIDIABETIC AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
| WO-1997028149-A1 | METHOD FOR RAISING HDL CHOLESTEROL LEVELS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |